

Flavio G Rocha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5390498/publications.pdf>

Version: 2024-02-01

99
papers

1,904
citations

304368

22
h-index

301761

39
g-index

102
all docs

102
docs citations

102
times ranked

2581
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and Validation of a Modified Eighth AJCC Staging System for Primary Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2022, 275, e773-e780.	2.1	13
2	Surgical Treatment of Neuroendocrine Tumors of the Terminal Ileum or Cecum: Ileocecectomy Versus Right Hemicolectomy. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1266-1274.	0.9	4
3	Surgical outcomes of gastroenteropancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma. <i>Journal of Surgical Oncology</i> , 2022, 126, 689-697.	0.8	4
4	Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTA) with Concomitant Systemic Gemcitabine and Cisplatin. <i>Annals of Surgical Oncology</i> , 2022, 29, 5462-5473.	0.7	16
5	Long-Term Outcomes after Spleen-Preserving Distal Pancreatectomy for Pancreatic Neuroendocrine Tumors: Results from the US Neuroendocrine Study Group. <i>Neuroendocrinology</i> , 2021, 111, 129-138.	1.2	12
6	Oncoplastic Breast-Conserving Surgery: Can We Reduce Rates of Mastectomy and Chemotherapy Use in Patients with Traditional Indications for Mastectomy?. <i>Annals of Surgical Oncology</i> , 2021, 28, 2199-2209.	0.7	8
7	ASO Author Reflections: Oncoplastic Surgery Facilitates Breast Conservation and May Permit More Judicious Chemotherapy Use. <i>Annals of Surgical Oncology</i> , 2021, 28, 2210-2211.	0.7	0
8	Recurrence of Nonfunctional Pancreatic Neuroendocrine Tumors After Curative Resection: A Tumor Burden-Based Prediction Model. <i>World Journal of Surgery</i> , 2021, 45, 2134-2141.	0.8	2
9	Indications and outcomes of enucleation versus formal pancreatectomy for pancreatic neuroendocrine tumors. <i>Hpb</i> , 2021, 23, 413-421.	0.1	18
10	Identifying Risk Factors and Patterns for Early Recurrence of Pancreatic Neuroendocrine Tumors: A Multi-Institutional Study. <i>Cancers</i> , 2021, 13, 2242.	1.7	6
11	Resection of pancreatic neuroendocrine tumors: defining patterns and time course of recurrence. <i>Hpb</i> , 2020, 22, 215-223.	0.1	20
12	Primary and metastatic melanoma of the GI tract: clinical presentation, endoscopic findings, and patient outcomes. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2020, 34, 4456-4462.	1.3	9
13	Tumor burden score predicts tumor recurrence of non-functional pancreatic neuroendocrine tumors after curative resection. <i>Hpb</i> , 2020, 22, 1149-1157.	0.1	13
14	Impact of perioperative blood transfusion on survival in pancreatic neuroendocrine tumor patients: analysis from the US Neuroendocrine Study Group. <i>Hpb</i> , 2020, 22, 1042-1050.	0.1	5
15	Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors. <i>Journal of Surgical Oncology</i> , 2020, 121, 480-485.	0.8	40
16	Intraoperative radiation therapy in early-stage breast cancer: Presence of lobular features is not associated with increased rate of requiring additional therapy. <i>American Journal of Surgery</i> , 2020, 220, 161-164.	0.9	3
17	Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis. <i>Annals of Surgical Oncology</i> , 2020, 27, 1203-1212.	0.7	21
18	Appendiceal Neuroendocrine Tumors: Does Colon Resection Improve Outcomes?. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2121-2126.	0.9	5

#	ARTICLE	IF	CITATIONS
19	Clinical relevance of performing endoscopic ultrasoundâ€­guided fineâ€­needle biopsy for pancreatic neuroendocrine tumors less than 2â€­cm. Journal of Surgical Oncology, 2020, 122, 1393-1400.	0.8	15
20	Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. ESMO Open, 2020, 5, e000668.	2.0	45
21	Evaluating Need for Additional Imaging and Biopsy After Oncoplastic Breast-Conserving Surgery. Annals of Surgical Oncology, 2020, 27, 3650-3656.	0.7	6
22	Surgical outcomes of patients with duodenal vs pancreatic neuroendocrine tumors following pancreatoduodenectomy. Journal of Surgical Oncology, 2020, 122, 442-449.	0.8	1
23	Incidence and impact of Textbook Outcome among patients undergoing resection of pancreatic neuroendocrine tumors: Results of the US Neuroendocrine Tumor Study Group. Journal of Surgical Oncology, 2020, 121, 1201-1208.	0.8	23
24	Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit. Journal of Surgical Oncology, 2020, 121, 1067-1073.	0.8	21
25	Central pancreatectomy with pancreaticogastrostomy reconstruction: A brief report and video technique. American Journal of Surgery, 2020, 219, 828-830.	0.9	3
26	Neuroendocrine Tumors of the Pancreatobiliary and Gastrointestinal Tracts. Surgical Clinics of North America, 2020, 100, 635-648.	0.5	21
27	Specific Growth Rate as a Predictor of Survival in Pancreatic Neuroendocrine Tumors: A Multi-institutional Study from the United States Neuroendocrine Study Group. Annals of Surgical Oncology, 2020, 27, 3915-3923.	0.7	2
28	Impact of Insurance Status on Survival in Gastroenteropancreatic Neuroendocrine Tumors. Annals of Surgical Oncology, 2020, 27, 3147-3153.	0.7	4
29	Oncoplastic breastâ€­conserving therapy and intraoperative radiotherapy for management of carcinoma in situ of the breast: A singleâ€­center experience. Breast Journal, 2020, 26, 2391-2394.	0.4	2
30	Oncoplastic breast conserving surgery is associated with a lower rate of surgical site complications compared to standard breast conserving surgery. American Journal of Surgery, 2019, 217, 138-141.	0.9	33
31	Interaction of race and pathology for neuroendocrine tumors: Epidemiology, natural history, or racial disparity?. Journal of Surgical Oncology, 2019, 120, 919-925.	0.8	10
32	Contemporary Review of Borderline Resectable Pancreatic Ductal Adenocarcinoma. Journal of Clinical Medicine, 2019, 8, 1205.	1.0	7
33	Association of preoperative monocyteâ€­toâ€­lymphocyte and neutrophilâ€­toâ€­lymphocyte ratio with recurrenceâ€­free and overall survival after resection of pancreatic neuroendocrine tumors (USâ€­NETSG). Journal of Surgical Oncology, 2019, 120, 632-638.	0.8	30
34	Therapeutic index of lymphadenectomy among patients with pancreatic neuroendocrine tumors: A multiâ€­institutional analysis. Journal of Surgical Oncology, 2019, 120, 1080-1086.	0.8	18
35	Impact of tumor size and nodal status on recurrence of nonfunctional pancreatic neuroendocrine tumors â‰¥2â€­cm after curative resection: A multiâ€­institutional study of 392 cases. Journal of Surgical Oncology, 2019, 120, 1071-1079.	0.8	47
36	Duodenal neuroendocrine tumors: Impact of tumor size and total number of lymph nodes examined. Journal of Surgical Oncology, 2019, 120, 1302-1310.	0.8	20

#	ARTICLE	IF	CITATIONS
37	Oncoplastic Central Partial Mastectomy and Neoareolar Reduction Mammoplasty with Immediate Nipple Reconstruction: An Initial Report of a Novel Option for Breast Conservation in Patients with Subareolar Tumors. <i>Annals of Surgical Oncology</i> , 2019, 26, 4284-4293.	0.7	6
38	Foreword. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, S1-S1.	0.7	0
39	Extreme oncoplasty: Expanding indications for breast conservation. <i>American Journal of Surgery</i> , 2019, 217, 851-856.	0.9	32
40	Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 651-658.	0.9	15
41	Small Bowel Necrosis After Colonoscopy. <i>Gastroenterology</i> , 2019, 156, e12-e13.	0.6	0
42	Significance of radiographic splenic vessel involvement in the pancreatic ductal adenocarcinoma of the body and tail of the gland. <i>Journal of Surgical Oncology</i> , 2019, 120, 262-269.	0.8	18
43	The conundrum of < 2-cm pancreatic neuroendocrine tumors: A preoperative risk score to predict lymph node metastases and guide surgical management. <i>Surgery</i> , 2019, 166, 15-21.	1.0	34
44	Defining the Role of Lymphadenectomy for Pancreatic Neuroendocrine Tumors: An Eight-Institution Study of 695 Patients from the US Neuroendocrine Tumor Study Group. <i>Annals of Surgical Oncology</i> , 2019, 26, 2517-2524.	0.7	38
45	Minimally invasive versus open distal pancreatectomy for pancreatic neuroendocrine tumors: An analysis from the U.S. neuroendocrine tumor study group. <i>Journal of Surgical Oncology</i> , 2019, 120, 231-240.	0.8	29
46	Evaluating the ACS NSQIP Risk Calculator in Primary Pancreatic Neuroendocrine Tumor: Results from the US Neuroendocrine Tumor Study Group. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 2225-2231.	0.9	10
47	Premalignant Lesions of the Biliary Tract. <i>Surgical Clinics of North America</i> , 2019, 99, 301-314.	0.5	3
48	Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. <i>American Surgeon</i> , 2019, 85, 1334-1340.	0.4	7
49	A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2019, 270, 422-433.	2.1	53
50	New Nodal Staging for Primary Pancreatic Neuroendocrine Tumors. <i>Annals of Surgery</i> , 2019, Publish Ahead of Print, e28-e35.	2.1	36
51	Gastric carcinoids: Does type of surgery or tumor affect survival?. <i>American Journal of Surgery</i> , 2019, 217, 937-942.	0.9	11
52	The impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An institution study from the US Neuroendocrine Tumor Study Group. <i>Journal of Surgical Oncology</i> , 2019, 119, 5-11.	0.8	5
53	Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 122-134.	0.9	22
54	Prognostic Role of Lymph Node Positivity and Number of Lymph Nodes Needed for Accurately Staging Small-Bowel Neuroendocrine Tumors. <i>JAMA Surgery</i> , 2019, 154, 134.	2.2	54

#	ARTICLE	IF	CITATIONS
55	Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. <i>Surgery</i> , 2019, 165, 657-663.	1.0	16
56	Margin status and long-term prognosis of primary pancreatic neuroendocrine tumor after curative resection: Results from the US Neuroendocrine Tumor Study Group. <i>Surgery</i> , 2019, 165, 548-556.	1.0	39
57	Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group. <i>American Surgeon</i> , 2019, 85, 1334-1340.	0.4	3
58	Oncoplastic reduction mammoplasty, an effective and safe method of breast conservation. <i>American Journal of Surgery</i> , 2018, 215, 910-915.	0.9	20
59	Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. <i>Journal of Surgical Oncology</i> , 2018, 117, 868-878.	0.8	36
60	Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?. <i>Annals of Surgical Oncology</i> , 2018, 25, 1052-1060.	0.7	5
61	Modified Appleby procedure for locally advanced pancreatic cancer. <i>American Journal of Surgery</i> , 2018, 215, 853-855.	0.9	10
62	Does mesenteric venous imaging assessment accurately predict pathologic invasion in localized pancreatic ductal adenocarcinoma?. <i>Hpb</i> , 2018, 20, 925-931.	0.1	6
63	Initiation of adjuvant therapy following surgical resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged?. <i>Journal of Surgical Oncology</i> , 2018, 117, 1655-1663.	0.8	16
64	Prognostic value of neutrophil-to-lymphocyte ratio (NLR) in intestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group.. <i>Journal of Clinical Oncology</i> , 2018, 36, 694-694.	0.8	2
65	Impact of insurance status on survival in neuroendocrine tumors: A multi-institutional Study from the U.S. Neuroendocrine Study Group.. <i>Journal of Clinical Oncology</i> , 2018, 36, 371-371.	0.8	0
66	Association of preoperative monocyte-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with overall survival after resection of pancreatic neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 216-216.	0.8	0
67	Gastric carcinoids: Does type of surgery or tumor affect survival?. <i>Journal of Clinical Oncology</i> , 2018, 36, 139-139.	0.8	0
68	Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective. <i>Annals of Surgical Oncology</i> , 2017, 24, 1722-1730.	0.7	33
69	What is a better predictor of clinically relevant postoperative pancreatic fistula (CR-POPF) following pancreaticoduodenectomy (PD): postoperative day one drain amylase (POD1DA) or the fistula risk score (FRS)?. <i>Hpb</i> , 2017, 19, 75-81.	0.1	30
70	Surgical strategies and novel therapies for locally advanced pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 16-24.	0.8	12
71	Circumferential pedicled omental flap for protection of portomesenteric venous reconstruction and gastroduodenal artery stump following pancreatoduodenectomy. <i>American Journal of Surgery</i> , 2017, 213, 983.	0.9	1
72	Validation of Fistula Risk Score calculator in diverse North American HPB practices. <i>Hpb</i> , 2017, 19, 508-514.	0.1	43

#	ARTICLE	IF	CITATIONS
73	Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-institution experience. <i>American Journal of Surgery</i> , 2017, 213, 94-99.	0.9	9
74	Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 365-365.	0.8	8
75	Gemcitabine/taxane adjuvant therapy in resected pancreatic cancer: A signal of improved survival?. <i>Journal of Clinical Oncology</i> , 2017, 35, 392-392.	0.8	0
76	Adjuvant therapy (AT) following resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged?. <i>Journal of Clinical Oncology</i> , 2017, 35, 373-373.	0.8	1
77	Extended neoadjuvant chemotherapy (CT) in borderline resectable pancreatic cancer (BRPC): Updated results.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15771-e15771.	0.8	0
78	Interferon-based Adjuvant Chemoradiation for Resected Pancreatic Head Cancer. <i>Annals of Surgery</i> , 2016, 263, 376-384.	2.1	21
79	Extended right hepatectomy with caudate lobe resection using the hilar "en bloc" resection technique with a modified hanging maneuver. <i>Journal of Surgical Oncology</i> , 2016, 113, 427-431.	0.8	5
80	Local resection for duodenal gastrointestinal stromal tumors. <i>American Journal of Surgery</i> , 2016, 211, 867-870.	0.9	16
81	Classification and techniques of en bloc venous reconstruction for pancreaticoduodenectomy. <i>Hpb</i> , 2016, 18, 827-834.	0.1	19
82	Preoperative computed tomography scan to predict pancreatic fistula after distal pancreatectomy using gland and tumor characteristics. <i>American Journal of Surgery</i> , 2016, 211, 871-876.	0.9	12
83	Pattern of CA19-9 response to neoadjuvant chemotherapy in locally advanced, borderline resectable pancreatic cancer to predict progression.. <i>Journal of Clinical Oncology</i> , 2016, 34, 321-321.	0.8	2
84	The Role of Biliary Carcinoembryonic Antigen-Related Cellular Adhesion Molecule 6 (CEACAM6) as a Biomarker in Cholangiocarcinoma. <i>PLoS ONE</i> , 2016, 11, e0150195.	1.1	15
85	Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 457-457.	0.8	2
86	Comparative analysis of resected duodenal and ampullary adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 362-362.	0.8	0
87	Overall survival (OS) in stage II resected pancreatic cancer (PC) using gemcitabine (Gem)/taxane adjuvant therapy (Rx): a single-institution experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, e15693-e15693.	0.8	0
88	Hybrid Push-Pull Endoscopic and Laparoscopic Full Thickness Resection for the Minimally Invasive Management of Gastrointestinal Stromal Tumors: A Pilot Clinical Study. <i>Gastroenterology Research and Practice</i> , 2015, 2015, 1-7.	0.7	4
89	A randomized, open-label, phase I/II trial of gemcitabine plus nab-paclitaxel with or without FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS500-TPS500.	0.8	0
90	Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival. <i>Annals of Surgical Oncology</i> , 2014, 21, 1530-1537.	0.7	127

#	ARTICLE	IF	CITATIONS
91	Dual-modality drainage of infected and symptomatic walled-off pancreatic necrosis: long-term clinical outcomes. <i>Gastrointestinal Endoscopy</i> , 2014, 79, 929-935.	0.5	138
92	Less invasive option for small hepatocellular carcinoma: thermal ablation as first-line therapy?. <i>Bulletin of the American College of Surgeons</i> , 2014, 99, 46-8.	0.3	0
93	Role of biliary CEACAM6 as a biomarker for cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 177-177.	0.8	0
94	Extended neoadjuvant chemotherapy (CT) in borderline resectable pancreas cancer (BRPC): Is preoperative chemoradiation (CRT) essential?. <i>Journal of Clinical Oncology</i> , 2013, 31, 236-236.	0.8	1
95	Extended neoadjuvant chemotherapy (CT) in borderline resectable pancreas cancer (BRPC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 4043-4043.	0.8	1
96	Resectability of colorectal liver metastases: an evolving definition. <i>Hpb</i> , 2012, 14, 283-284.	0.1	28
97	Intraductal papillary neoplasm of the bile duct: A biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?. <i>Hepatology</i> , 2012, 56, 1352-1360.	3.6	229
98	Significance of CEACAM6 expression in biliary tract carcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 207-207.	0.8	0
99	Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2010, 17, 490-496.	1.4	111